GSE16879

Mucosal expression profiling in patients with inflammatory bowel disease before and after first infliximab treatment

Whole-study status Not suitable

Dataset does not meet the current suitability threshold.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

121 case / 12 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

We used microarrays to identify mucosal gene signatures predictive of response to infliximab (IFX) in patients with inflammatory bowel disease (IBD) and to gain more insight into the pathogenesis of IBD. Keywords: drug response and treatment effect

Overall design

Mucosal biopsies were obtained at endoscopy in actively inflamed mucosa from 61 IBD patients (24 ulcerative colitis (UC), 19 Crohn’s colitis (CDc) and 18 Crohn’s ileitis (CDi)), refractory to corticosteroids and/or immunosuppression, before and 4-6 weeks after (except for 1 CDc patient) their first infliximab infusion and in normal mucosa from 12 control patients (6 colon and 6 ileum). The patients were classified for response to infliximab based on endoscopic and histologic findings at 4-6 weeks after first infliximab treatment. Total RNA was isolated from intestinal mucosal biopsies, labelled and hybridized to Affymetrix Human Genome U133 Plus 2.0 Arrays.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
133 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Curated expression experiment linkage and source URL.

Expression Atlas accession
E-GEOD-16879
Available
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

21 linked publications 21 DOIs

Primary publication

  1. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PloS one, 2009

Related publications

  1. Combined Bulk and Single-Cell Transcriptomic Analysis to Reveal the Potential Influences of Intestinal Inflammatory Disease on Multiple Sclerosis. Inflammation, 2025
  2. Comprehensive analysis of monocyte palmitoylation-related genes IFITM3 and CCL3-CCR5 axis in crohn's disease progression: Insights from mendelian randomization, multi-omics integration, machine learning, and SHAP methodology. Computational biology and chemistry, 2026
  3. Identification of cholesterol homeostasis related genes and potential pathogenesis mechanisms in ulcerative colitis. The Journal of steroid biochemistry and molecular biology, 2025
  4. Acetyl tributyl citrate induces intestinal toxicity by regulating the IDH2/NF-κB pathway and lipid peroxidation. Toxicology, 2026
  5. Potential Pathogenic Genes and Mechanism of Ankylosing Spondylitis: A Study Based on WGCNA and Bioinformatics Analysis. World neurosurgery, 2022
  6. Identification and multimodal characterization of a specialized epithelial cell type associated with Crohn's disease. Nature communications, 2024
  7. Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis. Autoimmunity, 2022
  8. Formylated Peptide Receptor-1-Mediated Gut Inflammation as a Therapeutic Target in Inflammatory Bowel Disease. Crohn's & colitis 360, 2024
  9. Targeting hyaluronan synthesis enhances the therapeutic effectiveness of biologics in inflammatory bowel disease. JCI insight, 2025
  10. Immunological profile of lactylation-related genes in Crohn's disease: a comprehensive analysis based on bulk and single-cell RNA sequencing data. Journal of translational medicine, 2024
  11. S-palmitoylation-related genes in Crohn's disease: Bioinformatic identification and validation. Biomolecules & biomedicine, 2025
  12. Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis. Journal of inflammation research, 2023
  13. Identification of Targets for Subsequent Treatment of Crohn's Disease Patients After Failure of Anti-TNF Therapy. Journal of inflammation research, 2023
  14. Identification and Experimental Validation of Oxidative Stress-Related Biomarkers in Ulcerative Colitis Using Machine Learning. Journal of inflammation research, 2025
  15. Investigating regulatory patterns of NLRP3 Inflammasome features and association with immune microenvironment in Crohn's disease. Frontiers in immunology, 2022
  16. Multi-omics derivation of a core gene signature for predicting therapeutic response and characterizing immune dysregulation in inflammatory bowel disease. Frontiers in immunology, 2025
  17. Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network. Frontiers in medicine, 2021
  18. Comprehensive analysis of anoikis-related gene signature in ulcerative colitis using machine learning algorithms. Frontiers in medicine, 2025
  19. Enrichment of Activated Fibroblasts as a Potential Biomarker for a Non-Durable Response to Anti-Tumor Necrosis Factor Therapy in Patients with Crohn's Disease. International journal of molecular sciences, 2023
  20. Genetic and dietary modulators of the inflammatory response in the gastrointestinal tract of the BXD mouse genetic reference population. eLife, 2023
Available

Metadata Quality Components

Analysis Readiness

Ready after review
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

No readiness blockers detected.

Next Steps

  • Verify the proposed sample assignments and case-versus-control comparison against the GEO metadata before using them in DESeq2 or another differential-expression tool.
  • Confirm processed count files and sample identifiers match the exported metadata.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Not suitable Dataset does not meet the current suitability threshold.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Assay differs from search intent Microarray Search intent expects bulk RNA-seq. Assay came from Normalization rules.
  • Disease context Crohn's disease, inflammatory bowel disease, ulcerative colitis Disease context came from Normalization rules.
  • Likely case group Ulcerative colitis 121 samples
  • Likely control group Control 12 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded assay: microarray cohorts are separated from the RNA-seq intent. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Disease/model vs control. Specimen: Biopsy. Comparison suitability: 0%.
  • Interpreted disease metadata: Crohn's disease, Inflammatory bowel disease, Ulcerative colitis.
  • Processed data is available for downstream review.
  • External evidence: Expression Atlas curated experiment link is available.
  • External evidence: PubMed links 21 publications; 21 DOIs available: PMID 19956723, PMID 34650991, PMID 34775094, PMID 35876170, PMID 36685554.
  • Publication context: Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.. PloS one, 2009. PMID 19956723. DOI 10.1371/journal.pone.0007984.
  • Publication context: Novel Gene Signatures Predicting Primary Non-response to Infliximab in Ulcerative Colitis: Development and Validation Combining Random Forest With Artificial Neural Network.. Frontiers in medicine, 2021. PMID 34650991. DOI 10.3389/fmed.2021.678424.
  • Publication context: Potential Pathogenic Genes and Mechanism of Ankylosing Spondylitis: A Study Based on WGCNA and Bioinformatics Analysis.. World neurosurgery, 2022. PMID 34775094. DOI 10.1016/j.wneu.2021.11.014.
  • Publication context: 18 additional linked PubMed publications are available.

Cautions

  • Downgraded assay: microarray cohorts are separated from the RNA-seq intent.
  • Disease/control design without a tumor/normal comparison is outside tumor/normal triage.
  • Microarray expression context downgraded below primary bulk RNA-seq for the default tissue ranking.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because microarray cohorts should be compared separately from RNA-seq cohorts.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

showing 500 of 587 fields

Sample Group Preview

showing 62 of 133 preview rows
Show Hide
Study totals: Case 121 | Control 12 | Unassigned 0 | Excluded 0 | Ambiguous 0 showing 62 of 133 preview rows
Group Role Accession Title Source / characteristics Reason
Ulcerative colitis Case GSM364633 UCR1_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364634 UCR2_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364635 UCR3_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364636 UCR4_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364637 UCR5_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364638 UCR6_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364639 UCR7_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364640 UCR8_beforeT Colonic mucosal biopsy from UC responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364641 UCNR1_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364642 UCNR2_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364643 UCNR3_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364644 UCNR4_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364645 UCNR5_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364646 UCNR6_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364647 UCNR7_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364648 UCNR8_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364649 UCNR9_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364650 UCNR10_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364651 UCNR11_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364652 UCNR12_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364653 UCNR13_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364654 UCNR14_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364655 UCNR15_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM364656 UCNR16_beforeT Colonic mucosal biopsy from UC non-responder before first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: Before first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422963 UCR1_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422965 UCR2_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422967 UCR3_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422969 UCR4_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422971 UCR5_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422973 UCR6_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422975 UCR7_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422977 UCR8_afterT Colonic mucosal biopsy from UC responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422979 UCNR1_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422981 UCNR2_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422983 UCNR3_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422985 UCNR4_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422987 UCNR5_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422989 UCNR6_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422991 UCNR7_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422993 UCNR8_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422995 UCNR9_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422997 UCNR10_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM422999 UCNR11_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM423001 UCNR12_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM423003 UCNR13_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM423005 UCNR14_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM423007 UCNR15_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Ulcerative colitis Case GSM423009 UCNR16_afterT Colonic mucosal biopsy from UC non-responder after first infliximab treatment Tissue: Colon; Disease: UC; Response to infliximab: No; Before or after first infliximab treatment: After first infliximab treatment Case marker detected.
Cd Case GSM423010 CDcR1_beforeT Colonic mucosal biopsy from CDc responder before first infliximab treatment Tissue: Colon; Disease: CD; Response to infliximab: Yes; Before or after first infliximab treatment: Before first infliximab treatment Explicit characteristic comparison arm detected.
Cd Case GSM423011 CDcR1_afterT Colonic mucosal biopsy from CDc responder after first infliximab treatment Tissue: Colon; Disease: CD; Response to infliximab: Yes; Before or after first infliximab treatment: After first infliximab treatment Explicit characteristic comparison arm detected.
71 additional case samples are hidden from this preview.
Control Control GSM364627 CO1 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364628 CO2 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364629 CO3 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364630 CO4 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364631 CO5 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM364632 CO6 Colonic mucosal biopsy from control individual Tissue: Colon; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM423047 IL1 Ileal mucosal biopsy from control individual Tissue: Ileum; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM423048 IL2 Ileal mucosal biopsy from control individual Tissue: Ileum; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM423049 IL3 Ileal mucosal biopsy from control individual Tissue: Ileum; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM423050 IL4 Ileal mucosal biopsy from control individual Tissue: Ileum; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM423051 IL5 Ileal mucosal biopsy from control individual Tissue: Ileum; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.
Control Control GSM423052 IL6 Ileal mucosal biopsy from control individual Tissue: Ileum; Disease: Control; Response to infliximab: Not applicable; Before or after first infliximab treatment: Not applicable Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.